MX2024007906A - Sal farmaceuticamente aceptable y forma cristalina del agonista receptor glp-1 y metodo de preparacion del mismo. - Google Patents

Sal farmaceuticamente aceptable y forma cristalina del agonista receptor glp-1 y metodo de preparacion del mismo.

Info

Publication number
MX2024007906A
MX2024007906A MX2024007906A MX2024007906A MX2024007906A MX 2024007906 A MX2024007906 A MX 2024007906A MX 2024007906 A MX2024007906 A MX 2024007906A MX 2024007906 A MX2024007906 A MX 2024007906A MX 2024007906 A MX2024007906 A MX 2024007906A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salt
crystalline form
glp
receptor agonist
Prior art date
Application number
MX2024007906A
Other languages
English (en)
Spanish (es)
Inventor
Zhenxing Du
Feng He
Qiyun Shao
Weidong Lu
Jun Feng
Junran Yang
Gujun Xu
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2024007906A publication Critical patent/MX2024007906A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2024007906A 2021-12-23 2022-12-23 Sal farmaceuticamente aceptable y forma cristalina del agonista receptor glp-1 y metodo de preparacion del mismo. MX2024007906A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111584574 2021-12-23
PCT/CN2022/141418 WO2023116882A1 (zh) 2021-12-23 2022-12-23 一种glp-1受体激动剂的可药用盐、结晶形式及其制备方法

Publications (1)

Publication Number Publication Date
MX2024007906A true MX2024007906A (es) 2024-07-10

Family

ID=86901360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007906A MX2024007906A (es) 2021-12-23 2022-12-23 Sal farmaceuticamente aceptable y forma cristalina del agonista receptor glp-1 y metodo de preparacion del mismo.

Country Status (12)

Country Link
US (1) US20250049777A1 (cg-RX-API-DMAC7.html)
EP (2) EP4455141B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024547113A (cg-RX-API-DMAC7.html)
KR (1) KR20240125003A (cg-RX-API-DMAC7.html)
CN (1) CN118434730A (cg-RX-API-DMAC7.html)
AU (1) AU2022418658A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241670A1 (cg-RX-API-DMAC7.html)
DK (1) DK4455141T3 (cg-RX-API-DMAC7.html)
ES (1) ES3069025T3 (cg-RX-API-DMAC7.html)
MX (1) MX2024007906A (cg-RX-API-DMAC7.html)
TW (1) TW202328114A (cg-RX-API-DMAC7.html)
WO (1) WO2023116882A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
AU2025207498A1 (en) * 2024-01-09 2026-07-09 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Glp-1r agonist pharmaceutical composition and use thereof
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3045644C (en) * 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
EA202191432A1 (ru) * 2018-11-22 2021-10-14 Цилу Регор Терапьютикс Инк. Агонисты glp-1r и их применения
WO2021249492A1 (zh) * 2020-06-10 2021-12-16 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用
JP7812052B2 (ja) * 2020-09-01 2026-02-09 江蘇恒瑞医薬股▲ふん▼有限公司 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
CN117177970A (zh) * 2021-04-30 2023-12-05 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
EP4732838A3 (en) 2026-07-01
US20250049777A1 (en) 2025-02-13
EP4455141A1 (en) 2024-10-30
EP4455141B1 (en) 2026-03-25
EP4455141A4 (en) 2025-04-09
CA3241670A1 (en) 2023-06-29
EP4732838A2 (en) 2026-04-29
KR20240125003A (ko) 2024-08-19
CN118434730A (zh) 2024-08-02
JP2024547113A (ja) 2024-12-26
TW202328114A (zh) 2023-07-16
AU2022418658A1 (en) 2024-07-11
WO2023116882A1 (zh) 2023-06-29
DK4455141T3 (da) 2026-04-27
ES3069025T3 (en) 2026-06-03

Similar Documents

Publication Publication Date Title
CA3241670A1 (en) Pharmaceutically acceptable salt and crystalline form of glp-1 receptor agonist and preparation method therefor
MX2024007907A (es) Forma cristalina del agonista del receptor de peptido 1 similar al glucagon y metodo de preparacion del mismo.
ES3066183T3 (en) 2-(((2,3-dihydrobenzo[b][1,4]dioxan-5-yl)piperidin-1-yl)methyl)-1-((oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid derivatives and similar compounds as glp-1 modulators for the treatment of diabetes
CA2419552C (en) Substituted pyrazoles
MX2023002979A (es) Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos.
CY1108786T1 (el) Ν-αρυλσουλφονυλ-3-υποκατεστημενα ινδολια που εχουν συναφεια υποδοχεα σεροτονινης, μεθοδος για τη παρασκευη αυτων και φαρμακευτικη συνθεση περιεχουσα αυτα
MY194461A (en) N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
US20110281840A1 (en) N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity
AR091771A2 (es) Compuesto 2,3-dihidro-6-nitroimidazo[2,1-b]oxazol
MX2025011326A (es) Formas polimorficas y sales de un agonista de glp-1r
JP2007528883A5 (cg-RX-API-DMAC7.html)
JP2006501273A5 (cg-RX-API-DMAC7.html)
CY1125531T1 (el) Μεθοδος παρασκευης της 5-[[4-[2-[5-(1- υδροξυαιθυλ)-2-πυριδι-νυλ]αιθοξυ]φαινυλ]μεθυλ]- 2,4-θειαζολιδινεδιονη και των αλατων της
BR0309277A (pt) Processo para preparação de um composto
MX2022011582A (es) Formas cristalinas de un agonista del receptor farnesoide x.
Liu et al. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546)
PE20010954A1 (es) Bencimidazoles, su preparacion y su empleo como medicamentos
RU2007119638A (ru) Новые индольные или бензимидазольные производные
NZ585428A (en) Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction
RU2008129625A (ru) Замещенные производные оксазола с аналгетическим действием
CO5261525A1 (es) Forma poliformica de un antagonista de los receptores de las taquiquininas .
UY27694A1 (es) Forma de administración para la aplicación oral de éster etilico del ácido 3-((2-((4- (hexiloxicarbonilamino-amino-metil)- fenilamino)metil)-1-metil-1 h -bencimidazol-5-carbonil)-piridin-2il-amino)-procíonico y las sales del mismo.
JP2004525983A5 (cg-RX-API-DMAC7.html)
MY199479A (en) Pharmaceutical composition and method for preparing same
DE602006010329D1 (de) Verfahren zur herstellung eines indolon-derivats